Davos Alzheimers Collaborative Inc

The davos alzheimer's collaborative's global cohort development program focuses on building a diverse and sustainable network of cohorts to advance alzheimer's disease (ad) and related dementias (adrd) research. This includes partnerships such as the collaboration with aga khan university in nairobi, kenya, where cognitive tests, saliva-based polygenic risk scores, and digital cognitive assessments are being validated in east african populations to create a clinical trial-ready cohort. In south korea, dac has acquired blood samples from 300 participants in a highly characterized cohort, advancing the validation of blood-based biomarkers (bbms) for global use. The project also includes access to 1,000 blood samples from a long-standing cohort in the latam/caribbean region for ad blood biomarker validation, as well as a large-scale clinical trial recruitment effort in the dominican republic, with over 14,000 participants across urban and rural settings.further expanding global research, dac is developing scalable approaches in egypt for early detection, monitoring, and risk reduction of ad, while in india, the "eye-dea study" is using cataract surgery clinics to assess ocular, speech, and olfactory biomarkers related to cognitive impairment. In chile, dac is collecting a wide range of data from a 9,000-person cohort to generate local validation data for blood biomarkers and digital cognitive assessments, particularly focusing on the impact of pesticide use and exposure to neurotoxins. These efforts are helping to ensure that ad research is inclusive of diverse populations and adaptable to local settings, with the aim of improving early detection, diagnosis, and treatment on a global scale.

The davos alzheimer's collaborative's global clinical trial program is maintaining a network of more than 30 european sites organized to accelerate studies and implement novel trial designs. This effort is part of dac's broader goal to build infrastructure for future pharmacological and non-pharmacological trials globally. Through the global cohort development program, dac is working to create clinical trial-ready populations by 2025, ensuring that diverse and well-characterized cohorts are prepared for both types of interventions. This will expand opportunities for global clinical trials, enhancing the ability to test new treatments and approaches in alzheimer's disease (ad) and related dementias (adrd) across varied populations and settings.